Cardiovascular Systems, Inc.
https://csi360.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardiovascular Systems, Inc.
The Biotech Rollercoaster Ride: From Lab To Buyout
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
Vifor Bulks Up Renal Franchise With Sanifit And Inositec Acquisitions
A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.
Listen Up! Big Things Happening In The World Of Audiology
From innovation to legislation, the US audiology market is being shaped by cutting-edge technology from device makers and legislation from the Biden administration to get more hearing aids to those that need them.
Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Replidyne, Inc.
- Shturman Cardiology Systems, Inc.